CD166 (ALCAM) Monoclonal Antibody (3A6), PE, eBioscience™, Invitrogen™

Description

• Description: This 3A6 monoclonal antibody reacts with human CD166, which is also known as activated leukocyte cell adhesion molecule (ALCAM)
• CD166 is an immunoglobulin superfamily cell adhesion molecule that is broadly expressed on developing and adult hematopoietic (e.g., activated T and B cells, monocytes, and dendritic cells) and non-hematopoietic (e.g., neural, endothelial, and epithelial) tissues
• CD166 has also been detected in melanoma, colorectal carcinoma, as well as cancers of the breast, prostate, and bladder
• CD166 mediates cell-cell adhesion by forming low-affinity homophilic interactions (ALCAM-ALCAM) or high-affinity heterophilic interactions with its ligand CD6 (ALCAM-CD6)
• CD166 plays a role in development, inflammation, and neutrophil migration
• Moreover, its expression can be used as a prognostic marker for several cancers and has been reported to be a cancer stem cell marker
• The 3A6 antibody has been reported to induce the internalization of CD166 and its recycling back to the cell surface
• Applications Reported: This 3A6 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This 3A6 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at 5 μL (0.06 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• This gene encodes activated leukocyte cell adhesion molecule (ALCAM), also known as CD166 (cluster of differentiation 166), which is a member of a subfamily of immunoglobulin receptors with five immunoglobulin-like domains (VVC2C2C2) in the extracellular domain
• This protein binds to T-cell differentiation antigene CD6, and is implicated in the processes of cell adhesion and migration
• Multiple alternatively spliced transcript variants encoding different isoforms have been found.